Journal of VirologySystems BiologyPeer-reviewed journal article
Genome-scale analysis of cellular restriction factors that inhibit transgene expression from adeno-associated virus vectors
Abstract
Adeno-associated virus (AAV) vectors are one of the leading platforms for gene delivery for the treatment of human genetic diseases, but the antiviral cellular mechanisms that interfere with optimal transgene expression are incompletely understood. Here, we performed two genome-scale CRISPR screens to identify cellular factors that restrict transgene expression from recombinant AAV vectors. Our screens revealed several components linked to DNA damage response, chromatin remodeling and transcriptional regulation. Inactivation of the Fanconi Anemia gene FANCA, the Human Silencing Hub (HUSH) associated methyltransferase SETDB1 and the gyrase, Hsp90, histidine kinase and MutL (GHKL)-type ATPase MORC3 led to increased transgene expression. Moreover, SETDB1 and MORC3 knockout improved transgene levels of several AAV serotypes as well as other viral vectors, such as lentivirus and adenovirus. Finally, we demonstrated that inhibition of FANCA, SETDB1 or MORC3 also enhanced transgene expression in human primary cells, suggesting that these could be physiologically relevant pathways that restrict AAV transgene levels in therapeutic settings. IMPORTANCERecombinant AAV (rAAV) vectors have been successfully developed for the treatment of genetic diseases. The therapeutic strategy often involves the replacement of a defective gene by expression of a functional copy from the rAAV vector genome. However, cells possess antiviral mechanisms that recognize and silence foreign DNA elements thereby limiting transgene expression and its therapeutic effect. Here, we utilize a functional genomics approach to uncover a comprehensive set of cellular restriction factors that inhibit rAAV-based transgene expression. Genetic inactivation of selected restriction factors increased rAAV transgene expression. Hence, modulation of identified restriction factors has the potential to enhance AAV gene replacement therapies.
- Citations
- 19
- FWCI
- 2.82
- Field percentile
- top 8%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- CTCF regulates wild-type and recombinant AAV gene expression by shaping viral chromatin
Clairine I. S. Larsen, Rhiannon R. Abrahams, … Kinjal Majumder·bioRxiv·Jun 3, 2026
- Transgene Expression in Cultured Cells Using Unpurified Recombinant Adeno-Associated Viral Vectors
Brian Benyamini, Meagan N. Esbin, … Anna C. Maurer·Journal of Visualized ExperimentsPeer-reviewed·Oct 20, 2023
- Capsid-mediated chromatin state of the AAV vector genome controls host species range
Adriana Gonzalez‐Sandoval, Shinnosuke Tsuji, … Mark A. Kay·bioRxiv·Oct 6, 2022
- RNAi-mediated rheostat for dynamic control of AAV-delivered transgenes
Megha P. Subramanian, James McIninch, … Vasant Jadhav·Nature CommunicationsPeer-reviewed·Apr 8, 2023
- CRISPR screen for rAAV production implicates genes associated with infection
E. O'Driscoll, Sakshi Arora, … Ophir Shalem·Molecular Therapy — Methods & Clinical DevelopmentPeer-reviewed·Jan 18, 2025
- Double-Strand Break Repair Pathways Differentially Affect Processing and Transduction by Dual AAV Vectors
Anna C. Maurer, Brian Benyamini, … Robert Tjian·Nature CommunicationsPeer-reviewed·Feb 11, 2025